With a diagnosis of NB, patients are stratified into one of three Children’s Oncology Group (COG) risk categories (low, intermediate, or high risk) based upon patient age at diagnosis, MYCN amplification status, histological features, tumor ploidy, clinical symptomology, extent of surgical resection, and International NB Risk Group Staging System (INRGSS) tumor stage [2]. This evidence concerns the gene MYCN and neuroblastoma.